Jelena Urosevic
Overview
Explore the profile of Jelena Urosevic including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
870
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Vora S, Chatterjee S, Andrew A, Kumar R, Proctor M, Zeng Z, et al.
Cell Death Dis
. 2025 Jan;
16(1):7.
PMID: 39779678
Polyploidy is a common outcome of chemotherapies, but there is conflicting evidence as to whether polyploidy is an adverse, benign or even favourable outcome. We show Aurora B kinase inhibitors...
2.
Vora S, Andrew A, Kumar R, Nazareth D, Bonfim-Melo A, Lim Y, et al.
Cell Death Dis
. 2024 Nov;
15(11):810.
PMID: 39521795
Aurora B kinase (AURKB) inhibitors have been trialled in a range of different tumour types but are not approved for any indication. Expression of the human papilloma virus (HPV) oncogenes...
3.
Smith J, Barlaam B, Beattie D, Bradshaw L, Chan H, Chiarparin E, et al.
J Med Chem
. 2024 Jul;
67(16):13604-13638.
PMID: 39080842
PRMT5, a type 2 arginine methyltransferase, has a critical role in regulating cell growth and survival in cancer. With the aim of developing MTA-cooperative PRMT5 inhibitors suitable for MTAP-deficient cancers,...
4.
Vasalou C, Proia T, Kazlauskas L, Przybyla A, Sung M, Mamidi S, et al.
CPT Pharmacometrics Syst Pharmacol
. 2024 Mar;
13(6):994-1005.
PMID: 38532525
Trastuzumab deruxtecan (T-DXd; DS-8201; ENHERTU®) is a human epithelial growth factor receptor 2 (HER2)-directed antibody drug conjugate (ADC) with demonstrated antitumor activity against a range of tumor types. Aiming to...
5.
Urosevic J, Stankovic D, Jokanovic D, Trivan G, Rodzkin A, Jovic D, et al.
Plants (Basel)
. 2024 Mar;
13(5).
PMID: 38475581
Elevated concentrations of heavy metals result in soil degradation, a reduction in plant yields, and a lower quality of agricultural products, which directly endangers people, animals, and the ecosystem. The...
6.
Hopcroft L, Wigmore E, Williamson S, Ros S, Eberlein C, Moss J, et al.
NPJ Breast Cancer
. 2023 Sep;
9(1):76.
PMID: 37726304
No abstract available.
7.
Lawson M, Cureton N, Ros S, Cheraghchi-Bashi A, Urosevic J, DArcy S, et al.
Cancer Res
. 2023 Sep;
83(23):3989-4004.
PMID: 37725704
Significance: Camizestrant, a next-generation oral SERD, shows promise in preclinical models of ER+ breast cancer alone and in combination with CDK4/6 and PI3K/AKT/mTOR inhibitors to address endocrine resistance, a current...
8.
Hopcroft L, Wigmore E, Williamson S, Ros S, Eberlein C, Moss J, et al.
NPJ Breast Cancer
. 2023 Aug;
9(1):69.
PMID: 37596288
No abstract available.
9.
Hopcroft L, Wigmore E, Williamson S, Ros S, Eberlein C, Moss J, et al.
NPJ Breast Cancer
. 2023 Aug;
9(1):64.
PMID: 37543694
Combining the selective AKT inhibitor, capivasertib, and SERD, fulvestrant improved PFS in a Phase III clinical trial (CAPItello-291), treating HR+ breast cancer patients following aromatase inhibitors, with or without CDK4/6...
10.
Bertran-Alamillo J, Gimenez-Capitan A, Roman R, Talbot S, Whiteley R, Floch N, et al.
Mol Cancer
. 2023 Jul;
22(1):110.
PMID: 37443114
Background: Drugs targeting the spindle assembly checkpoint (SAC), such as inhibitors of Aurora kinase B (AURKB) and dual specific protein kinase TTK, are in different stages of clinical development. However,...